Department of Physiology, College of Medicine, Nanchang University, Nanchang 330006, China; Department of Stomatology, Affiliated Third Hospital of Soochow University, The First People's Hospital of Changzhou, Changzhou 213003, China.
Department of Physiology, College of Medicine, Nanchang University, Nanchang 330006, China.
Life Sci. 2021 Jun 15;275:119321. doi: 10.1016/j.lfs.2021.119321. Epub 2021 Mar 9.
Hepatic ischemia reperfusion injury (HIRI) is an important cause of liver dysfunction after liver transplantation for the patients suffered from fatty liver, non-alcoholic cirrhosis, or liver cancer. It is closely related to liver cells apoptosis. Therefore, how to maintain the stable state of cell apoptosis is important to protect the liver from HIRI. Drug treatment basically applies some active substances directly or indirectly, reducing HIRI. But their toxic side effects limit the clinical applications. Differently, non-drug treatment means making use of other kinds of measures to reduce the damage, such as non-pharmaceutical preparations, surgical methods, inhalation or perfusion gas, and so on. Non-drug treatments have been shown to balance cell apoptosis and reduce liver damage during HIRI. This review summarized the progresses in the roles of non-drug treatments on liver cells apoptosis during HIRI in recent years, focusing on apoptosis inducing factors, its signal transduction pathway, and downstream molecules, etc., expecting to elucidate non-drug treatments of anti-HIRI more systematically.
肝缺血再灌注损伤（HIRI）是脂肪肝、非酒精性肝硬化或肝癌患者肝移植后肝功能障碍的重要原因。它与肝细胞凋亡密切相关。因此，如何维持细胞凋亡的稳定状态对于保护肝脏免受 HIRI 至关重要。药物治疗基本上是直接或间接地应用一些活性物质，以减轻 HIRI。但它们的毒副作用限制了临床应用。相反，非药物治疗是指利用其他各种措施来减少损伤，如非药物制剂、手术方法、吸入或灌注气体等。非药物治疗已被证明可以在 HIRI 期间平衡细胞凋亡并减轻肝损伤。本综述总结了近年来非药物治疗在 HIRI 期间对肝细胞凋亡作用的研究进展，重点介绍了凋亡诱导因子、其信号转导途径和下游分子等，期望更系统地阐明非药物抗 HIRI 治疗。
